SF
STAMATINA FRAGKOGIANNI
Also known as: Matina Fragkogianni
Tempus Labs (United States), Memorial Sloan Kettering Cancer Center, University of Edinburgh, University of Crete
Research areas: Biochemistry, Genetics and Molecular Biology · Cancer Research · Cancer Genomics and Diagnostics · Lung Cancer Treatments and Mutations · BRCA gene mutations in cancer
0000-0002-5960-8921
Employment
-
Tempus Labs (United States) Associate Director, Data Science2022 - Present
-
Memorial Sloan-Kettering Cancer Center Postdoctoral Fellow2019 - 2022
-
The University of Edinburgh Postdoctoral Fellow2017 - 2019
-
University of Edinburgh Graduate Student2013 - 2017
-
Barcelona Supercomputing Center Bioinformatics technician2012 - 2013
Education
-
The University of Edinburgh PhD in Bioinformatics2013 - 2017
-
The University of Edinburgh MSc in Bioinformatics2011 - 2012
-
University of Crete BSc in Computer Science2005 - 2011
Projects & Funding
Projects & funding information is unavailable.
Publications (29)
- Data from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Figure S1 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Figure S2 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Figure S3 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Figure S4 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Figure S5 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Table S1 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Supplementary Table S2 from Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI) Save
- Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort Save
- Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. Save
- ESR1 mutations and associated alterations in patients with estrogen receptor (ER+), HER2-positive (HER2+) breast cancers at diagnosis of metastatic disease (mBC). Save
- ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC). Save
- Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in KRAS-STK11 NSCLC. Save
- Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI). Save
- Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study. Save
- Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality Save
- Molecular landscape of patients (pts) with metastatic breast cancer (mBC) who progressed on second-line (2L) selective estrogen receptor degraders (SERDs) Save
- Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers Save
- A microglia clonal inflammatory disorder in Alzheimer’s disease Save